1
|
Wang Q, Wu S, Zou J, Liang X, Mou C, Zheng P, Chi YR. NHC-catalyzed enantioselective access to β-cyano carboxylic esters via in situ substrate alternation and release. Nat Commun 2023; 14:4878. [PMID: 37573355 PMCID: PMC10423276 DOI: 10.1038/s41467-023-40645-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Accepted: 08/04/2023] [Indexed: 08/14/2023] Open
Abstract
A carbene-catalyzed asymmetric access to chiral β-cyano carboxylic esters is disclosed. The reaction proceeds between β,β-disubstituted enals and aromatic thiols involving enantioselective protonation of enal β-carbon. Two main factors contribute to the success of this reaction. One involves in situ ultrafast addition of the aromatic thiol substrates to the carbon-carbon double bond of the enal substrate. This reaction converts almost all enal substrate to a Thiol-click Intermediate, significantly reducing aromatic thiol substrates concentration and suppressing the homo-coupling reaction of enals. Another factor is an in situ release of enal substrate from the Thiol-click Intermediate for the desired reaction to proceed effectively. The optically enriched β-cyano carboxylic esters from our method can be readily transformed to medicines that include γ-aminobutyric acids derivatives such as Rolipram. In addition to synthetic utilities, our control of reaction outcomes via in situ substrate modulation and release can likely inspire future reaction development.
Collapse
Affiliation(s)
- Qingyun Wang
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, 550025, China
| | - Shuquan Wu
- Center for Industrial Catalysis and Cleaning Process Development, School of Chemical Engineering, Guizhou Minzu University, Guiyang, 550025, China
| | - Juan Zou
- School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China
| | - Xuyang Liang
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, 550025, China
| | - Chengli Mou
- School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China
| | - Pengcheng Zheng
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, 550025, China.
| | - Yonggui Robin Chi
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, 550025, China.
- School of Chemistry, Chemical Engineering, and Biotechnology, Nanyang Technological University, Singapore, 637371, Singapore.
| |
Collapse
|
2
|
Wang L, Zheng Y, Zhou X, Wang H, Yan Q, Wang W, Chen F. Synthesis of α-Aryl Nitriles via Nucleophilic Substitution of α-Cyanohydrin Methanesulfonates with Malonates. CHINESE J ORG CHEM 2023. [DOI: 10.6023/cjoc202208029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
|
3
|
Braconi L, Teodori E, Riganti C, Coronnello M, Nocentini A, Bartolucci G, Pallecchi M, Contino M, Manetti D, Romanelli MN, Supuran CT, Dei S. New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells. J Med Chem 2022; 65:14655-14672. [PMID: 36269278 DOI: 10.1021/acs.jmedchem.2c01175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In a continuing search of dual P-gp and hCA XII inhibitors, we synthesized and studied new N,N-bis(alkanol)amine aryl diester derivatives characterized by the presence of a coumarin group. These hybrids contain both P-gp and hCA XII binding groups to synergistically overcome the P-gp-mediated multidrug resistance (MDR) in cancer cells expressing both P-gp and hCA XII. Indeed, hCA XII modulates the efflux activity of P-gp and the inhibition of hCA XII reduces the intracellular pH, thereby decreasing the ATPase activity of P-gp. All compounds showed inhibitory activities on P-gp and hCA XII proteins taken individually, and many of them displayed a synergistic effect in HT29/DOX and A549/DOX cells that overexpress both P-gp and hCA XII, being more potent than in K562/DOX cells overexpressing only P-gp. Compounds 5 and 14 were identified as promising chemosensitizer agents for selective inhibition in MDR cancer cells overexpressing both P-gp and hCA XII.
Collapse
Affiliation(s)
- Laura Braconi
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| | - Elisabetta Teodori
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| | - Chiara Riganti
- Department of Oncology, University of Turin, Via Santena 5/bis, 10126Torino, Italy
| | - Marcella Coronnello
- Department of Health Sciences - Clinical Pharmacology and Oncology Section, University of Florence, Viale Pieraccini 6, 50139Firenze, Italy
| | - Alessio Nocentini
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| | - Gianluca Bartolucci
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| | - Marco Pallecchi
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| | - Marialessandra Contino
- Department of Pharmacy - Drug Sciences, University of Bari "A. Moro", via Orabona 4, 70125Bari, Italy
| | - Dina Manetti
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| | - Maria Novella Romanelli
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| | - Claudiu T Supuran
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| | - Silvia Dei
- Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019Sesto Fiorentino (FI), Italy
| |
Collapse
|
4
|
Affiliation(s)
- Yujie Xia
- State Key Laboratory of Luminescent Materials and Devices South China University of Technology Guangzhou 510640 China
| | - Huanfeng Jiang
- State Key Laboratory of Luminescent Materials and Devices South China University of Technology Guangzhou 510640 China
- State Key Laboratory of Pulp and Paper Engineering South China University of Technology Guangzhou 510640 China
| | - Wanqing Wu
- State Key Laboratory of Luminescent Materials and Devices South China University of Technology Guangzhou 510640 China
- State Key Laboratory of Pulp and Paper Engineering South China University of Technology Guangzhou 510640 China
| |
Collapse
|
5
|
Perin N, Hok L, Beč A, Persoons L, Vanstreels E, Daelemans D, Vianello R, Hranjec M. N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis. Eur J Med Chem 2020; 211:113003. [PMID: 33248847 DOI: 10.1016/j.ejmech.2020.113003] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 11/05/2020] [Accepted: 11/05/2020] [Indexed: 12/20/2022]
Abstract
We present the design, synthesis and biological activity of novel N-substituted benzimidazole based acrylonitriles as potential tubulin polymerization inhibitors. Their synthesis was achieved using classical linear organic and microwave assisted techniques, starting from aromatic aldehydes and N-substituted-2-cyanomethylbenzimidazoles. All newly prepared compounds were tested for their antiproliferative activity in vitro on eight human cancer cell lines and one reference non-cancerous assay. N,N-dimethylamino substituted acrylonitriles 30 and 41, bearing N-isobutyl and cyano substituents placed on the benzimidazole nuclei, showed strong and selective antiproliferative activity in the submicromolar range of inhibitory concentrations (IC50 0.2-0.6 μM), while being significantly less toxic than reference systems docetaxel and staurosporine, thus promoting them as lead compounds. Mechanism of action studies demonstrated that two most active compounds inhibited tubulin polymerization. Computational analysis confirmed the suitability of the employed benzimidazole-acrylonitrile skeleton for the binding within the colchicine binding site in tubulin, thus rationalizing the observed antitumor activities, and demonstrated that E-isomers are active substances. It also provided structural determinants affecting both the binding position and the matching affinities, identifying the attached NMe2 group as the most dominant in promoting the binding, which allows ligands to optimize favourable cation∙∙∙π and hydrogen bonding interactions with Lys352.
Collapse
Affiliation(s)
- N Perin
- Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev Trg 19, HR-10000, Zagreb, Croatia
| | - L Hok
- Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička cesta 54, HR-10000, Zagreb, Croatia
| | - A Beč
- Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev Trg 19, HR-10000, Zagreb, Croatia
| | - L Persoons
- KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium
| | - E Vanstreels
- KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium
| | - D Daelemans
- KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium
| | - R Vianello
- Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička cesta 54, HR-10000, Zagreb, Croatia.
| | - M Hranjec
- Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev Trg 19, HR-10000, Zagreb, Croatia.
| |
Collapse
|
6
|
Zhang H, Xu H, Ashby CR, Assaraf YG, Chen ZS, Liu HM. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev 2020; 41:525-555. [PMID: 33047304 DOI: 10.1002/med.21739] [Citation(s) in RCA: 130] [Impact Index Per Article: 32.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 09/01/2020] [Accepted: 09/28/2020] [Indexed: 12/13/2022]
Abstract
Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP-binding cassette (ABC) transporter superfamily is considered one of the primary causes for cancer MDR, in which the role of P-glycoprotein (P-gp/ABCB1) has been most well-established. The clinical co-administration of P-gp drug efflux inhibitors, in combination with anticancer drugs which are P-gp transport substrates, was considered to be a treatment modality to surmount MDR in anticancer therapy by blocking P-gp-mediated multidrug efflux. Extensive attempts have been carried out to screen for sets of nontoxic, selective, and efficacious P-gp efflux inhibitors. In this review, we highlight the recent achievements in drug design, characterization, structure-activity relationship (SAR) studies, and mechanisms of action of the newly synthetic, potent small molecules P-gp inhibitors in the past 5 years. The development of P-gp inhibitors will increase our knowledge of the mechanisms and functions of P-gp-mediated drug efflux which will benefit drug discovery and clinical cancer therapeutics where P-gp transporter overexpression has been implicated in MDR.
Collapse
Affiliation(s)
- Hang Zhang
- Key Laboratory of Advanced Drug Preparation Technologies, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
| | - Haiwei Xu
- Key Laboratory of Advanced Drug Preparation Technologies, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
| | - Charles R Ashby
- Department of Pharmaceutical Sciences, St. John's University, Queens, New York, USA
| | - Yehuda G Assaraf
- Department of Biology, The Fred Wyszkowski Cancer Research Laboratory, Technion-Israel Institute of Technology, Haifa, Israel
| | - Zhe-Sheng Chen
- Department of Pharmaceutical Sciences, St. John's University, Queens, New York, USA
| | - Hong-Min Liu
- Key Laboratory of Advanced Drug Preparation Technologies, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
| |
Collapse
|
7
|
Teodori E, Braconi L, Bua S, Lapucci A, Bartolucci G, Manetti D, Romanelli MN, Dei S, Supuran CT, Coronnello M. Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells. Molecules 2020; 25:molecules25071748. [PMID: 32290281 PMCID: PMC7181201 DOI: 10.3390/molecules25071748] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Revised: 04/01/2020] [Accepted: 04/08/2020] [Indexed: 11/16/2022] Open
Abstract
A new series of N,N-bis(alkanol)amine aryl diesters was synthesized and studied as dual P-glycoprotein (P-gp) and carbonic anhydrase XII inhibitors (CA XII). These hybrids should be able to synergistically overcome P-gp mediated multidrug resistance (MDR) in cancer cells. It was reported that the efflux activity of P-gp could be modulated by CA XII, as the pH reduction caused by CA XII inhibition produces a significant decrease in P-gp ATPase activity. The new compounds reported here feature both P-gp and CA XII binding moieties. These hybrids contain a N,N-bis(alkanol)amine diester scaffold found in P-glycoprotein ligands and a coumarin or benzene sulfonamide moiety to target CA XII. Many compounds displayed a dual activity against P-gp and CA XII being active in the Rhd 123 uptake test on K562/DOX cells and in the hCA XII inhibition test. On LoVo/DOX cells, that overexpress both P-gp and CA XII, some coumarin derivatives showed a high MDR reversal effect in Rhd 123 uptake and doxorubicin cytotoxicity enhancement tests. In particular, compounds 7 and 8 showed higher activity than verapamil and were more potent on LoVo/DOX than on K562/DOX cells overexpressing only P-gp. They can be considered as valuable candidates for selective P-gp/CA XII inhibition in MDR cancer cells.
Collapse
Affiliation(s)
- Elisabetta Teodori
- Department of Neuroscience, Psychology, Drug Research and Child’s Health–Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy; (E.T.); (L.B.); (S.B.); (G.B.); (D.M.); (M.N.R.); (C.T.S.)
| | - Laura Braconi
- Department of Neuroscience, Psychology, Drug Research and Child’s Health–Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy; (E.T.); (L.B.); (S.B.); (G.B.); (D.M.); (M.N.R.); (C.T.S.)
| | - Silvia Bua
- Department of Neuroscience, Psychology, Drug Research and Child’s Health–Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy; (E.T.); (L.B.); (S.B.); (G.B.); (D.M.); (M.N.R.); (C.T.S.)
| | - Andrea Lapucci
- Department of Health Sciences—Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy; (A.L.); (M.C.)
| | - Gianluca Bartolucci
- Department of Neuroscience, Psychology, Drug Research and Child’s Health–Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy; (E.T.); (L.B.); (S.B.); (G.B.); (D.M.); (M.N.R.); (C.T.S.)
| | - Dina Manetti
- Department of Neuroscience, Psychology, Drug Research and Child’s Health–Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy; (E.T.); (L.B.); (S.B.); (G.B.); (D.M.); (M.N.R.); (C.T.S.)
| | - Maria Novella Romanelli
- Department of Neuroscience, Psychology, Drug Research and Child’s Health–Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy; (E.T.); (L.B.); (S.B.); (G.B.); (D.M.); (M.N.R.); (C.T.S.)
| | - Silvia Dei
- Department of Neuroscience, Psychology, Drug Research and Child’s Health–Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy; (E.T.); (L.B.); (S.B.); (G.B.); (D.M.); (M.N.R.); (C.T.S.)
- Correspondence:
| | - Claudiu T. Supuran
- Department of Neuroscience, Psychology, Drug Research and Child’s Health–Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy; (E.T.); (L.B.); (S.B.); (G.B.); (D.M.); (M.N.R.); (C.T.S.)
| | - Marcella Coronnello
- Department of Health Sciences—Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy; (A.L.); (M.C.)
| |
Collapse
|
8
|
Dong J, Qin Z, Zhang WD, Cheng G, Yehuda AG, Ashby CR, Chen ZS, Cheng XD, Qin JJ. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resist Updat 2020; 49:100681. [PMID: 32014648 DOI: 10.1016/j.drup.2020.100681] [Citation(s) in RCA: 140] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Revised: 01/13/2020] [Accepted: 01/16/2020] [Indexed: 12/16/2022]
Abstract
The presence of multidrug resistance (MDR) in malignant tumors is one of the primary causes of treatment failure in cancer chemotherapy. The overexpression of the ATP binding cassette (ABC) transporter, P-glycoprotein (P-gp), which significantly increases the efflux of certain anticancer drugs from tumor cells, produces MDR. Therefore, inhibition of P-gp may represent a viable therapeutic strategy to overcome cancer MDR. Over the past 4 decades, many compounds with P-gp inhibitory efficacy (referred to as first- and second-generation P-gp inhibitors) have been identified or synthesized. However, these compounds were not successful in clinical trials due to a lack of efficacy and/or untoward toxicity. Subsequently, third- and fourth-generation P-gp inhibitors were developed but dedicated clinical trials did not indicate a significant therapeutic effect. In recent years, an extraordinary array of highly potent, selective, and low-toxicity P-gp inhibitors have been reported. Herein, we provide a comprehensive review of the synthetic and natural products that have specific inhibitory activity on P-gp drug efflux as well as promising chemosensitizing efficacy in MDR cancer cells. The present review focuses primarily on the structural features, design strategies, and structure-activity relationships (SAR) of these compounds.
Collapse
Affiliation(s)
- Jinyun Dong
- Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Zuodong Qin
- Research Center of Biochemical Engineering Technology, College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou 425199, China
| | - Wei-Dong Zhang
- School of Pharmacy, Naval Medical University, Shanghai, 200433, China
| | - Gang Cheng
- College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Assaraf G Yehuda
- The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, 3200003, Israel
| | - Charles R Ashby
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA
| | - Zhe-Sheng Chen
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
| | - Xiang-Dong Cheng
- Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
| | - Jiang-Jiang Qin
- Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
| |
Collapse
|
9
|
Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers. Eur J Med Chem 2019; 182:111655. [DOI: 10.1016/j.ejmech.2019.111655] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Revised: 08/26/2019] [Accepted: 08/27/2019] [Indexed: 12/23/2022]
|
10
|
Dei S, Braconi L, Romanelli MN, Teodori E. Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators. CANCER DRUG RESISTANCE (ALHAMBRA, CALIF.) 2019; 2:710-743. [PMID: 35582565 PMCID: PMC8992508 DOI: 10.20517/cdr.2019.31] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Revised: 06/03/2019] [Accepted: 06/13/2019] [Indexed: 02/06/2023]
Abstract
The development of multidrug resistance (MDR) is one of the major challenges to the success of chemotherapy treatment of cancer. This phenomenon is often associated with the overexpression of the ATP-binding cassette (ABC) transporters P-gp (P-glycoprotein, ABCB1), multidrug resistance-associated protein 1, ABCC1 and breast cancer resistance protein, ABCG2 (BCRP). These transporters are constitutively expressed in many tissues playing relevant protective roles by the regulation of the permeability of biological membranes, but they are also overexpressed in malignant tissues. P-gp is the first efflux transporter discovered to be involved in cancer drug resistance, and over the years, inhibitors of this pump have been disclosed to administer them in combination with chemotherapeutic agents. Three generations of inhibitors of P-gp have been examined in preclinical and clinical studies; however, these trials have largely failed to demonstrate that coadministration of pump inhibitors elicits an improvement in therapeutic efficacy of antitumor agents, although some of the latest compounds show better results. Therefore, new and innovative strategies, such as the fallback to natural products and the discover of dual activity ligands emerged as new perspectives. BCRP is the most recently ABC protein identified to be involved in multidrug resistance. It is overexpressed in several haematological and solid tumours together with P-gp, threatening the therapeutic effectiveness of different chemotherapeutic drugs. The chemistry of recently described BCRP inhibitors and dual P-gp/BCRP inhibitors, as well as their preliminary pharmacological evaluation are discussed, and the most recent advances concerning these kinds of MDR modulators are reviewed.
Collapse
Affiliation(s)
- Silvia Dei
- Department of Neuroscience, Psychology, Drug Research and Child's Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, Sesto Fiorentino (FI) 50019, Italy
| | - Laura Braconi
- Department of Neuroscience, Psychology, Drug Research and Child's Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, Sesto Fiorentino (FI) 50019, Italy
| | - Maria Novella Romanelli
- Department of Neuroscience, Psychology, Drug Research and Child's Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, Sesto Fiorentino (FI) 50019, Italy
| | - Elisabetta Teodori
- Department of Neuroscience, Psychology, Drug Research and Child's Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, Sesto Fiorentino (FI) 50019, Italy
| |
Collapse
|
11
|
Dei S, Braconi L, Trezza A, Menicatti M, Contino M, Coronnello M, Chiaramonte N, Manetti D, Perrone MG, Romanelli MN, Udomtanakunchai C, Colabufo NA, Bartolucci G, Spiga O, Salerno M, Teodori E. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators. Eur J Med Chem 2019; 172:71-94. [DOI: 10.1016/j.ejmech.2019.03.054] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Revised: 03/21/2019] [Accepted: 03/22/2019] [Indexed: 12/20/2022]
|
12
|
He SJ, Wang B, Lu X, Gong TJ, Yang YN, Wang XX, Wang Y, Xiao B, Fu Y. Copper-Catalyzed Reagent-Controlled Regioselective Cyanoborylation of Vinylarenes. Org Lett 2018; 20:5208-5212. [DOI: 10.1021/acs.orglett.8b02155] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Shi-Jiang He
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| | - Bing Wang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| | - Xi Lu
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| | - Tian-Jun Gong
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| | - Yi-Nuo Yang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| | - Xiao-Xu Wang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| | - Yan Wang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| | - Bin Xiao
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| | - Yao Fu
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Urban Pollutant Conversion, Anhui Province Key Laboratory of Biomass Clean Energy, iChEM, University of Science and Technology of China, Hefei 230026, China
| |
Collapse
|
13
|
Li J, Ma J, Xin Y, Quan Z, Tian Y. Synthesis and pharmacological evaluation of 2,3‐diphenyl acrylonitriles‐bearing halogen as selective anticancer agents. Chem Biol Drug Des 2018. [DOI: 10.1111/cbdd.13180] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jia‐Jun Li
- Key Laboratory of Natural Resources and Functional Molecules of the Changbai MountainAffiliated Ministry of EducationCollege of PharmacyYanbian University Yanji Jilin Province China
| | - Jun Ma
- Jiangsu Hansoh Pharmaceutical Group Co. Ltd. Lianyungang Jiangsu Province China
| | - Ya‐Bing Xin
- Key Laboratory of Natural Resources and Functional Molecules of the Changbai MountainAffiliated Ministry of EducationCollege of PharmacyYanbian University Yanji Jilin Province China
| | - Zhe‐Shan Quan
- Key Laboratory of Natural Resources and Functional Molecules of the Changbai MountainAffiliated Ministry of EducationCollege of PharmacyYanbian University Yanji Jilin Province China
| | - Yu‐Shun Tian
- Key Laboratory of Natural Resources and Functional Molecules of the Changbai MountainAffiliated Ministry of EducationCollege of PharmacyYanbian University Yanji Jilin Province China
| |
Collapse
|
14
|
Design and synthesis of new potent N,N -bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents. Eur J Med Chem 2018; 147:7-20. [DOI: 10.1016/j.ejmech.2018.01.092] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 01/18/2018] [Accepted: 01/28/2018] [Indexed: 01/06/2023]
|
15
|
Henkin JM, Ren Y, Soejarto DD, Kinghorn AD. The Search for Anticancer Agents from Tropical Plants. PROGRESS IN THE CHEMISTRY OF ORGANIC NATURAL PRODUCTS 2018; 107:1-94. [PMID: 30178270 DOI: 10.1007/978-3-319-93506-5_1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Many of the clinically used anticancer agents in Western medicine are derived from secondary metabolites found in terrestrial microbes, marine organisms, and higher plants, with additional compounds of this type being currently in clinical trials. If plants are taken specifically, it is generally agreed that the prospects of encountering enhanced small organic-molecule chemical diversity are better if tropical rather than temperate species are investigated in drug discovery efforts. Plant collection in tropical source countries requires considerable preparation and organization to conduct in a responsible manner that abides by the provisions of the 1992 Rio Convention of Biological Diversity and the 2010 Nagoya Protocol on Access to Genetic Resources. Correct taxonomic identifications and enhanced procedures for processing and documenting plant samples when collected in often difficult terrain are required. Phytochemical aspects of the work involve solvent fractionation, known compound dereplication, preliminary in vitro testing, and prioritization, leading to "activity-guided fractionation", compound structure determination, and analog development. Further evaluation of lead compounds requires solubility, formulation, preliminary pharmacokinetics, and in vivo testing in suitable models. Covering the work of the authors carried out in two sequential multidisciplinary, multi-institutional research projects, examples of very promising compounds discovered from plants acquired from Africa, Southeast Asia, the Americas, and the Caribbean region, and with potential anticancer activity will be mentioned. These include plant secondary metabolites of the diphyllin lignan, cyclopenta[b]benzofuran, triterpenoid, and tropane alkaloid types.
Collapse
Affiliation(s)
- Joshua M Henkin
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
| | - Yulin Ren
- Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - Djaja Djendoel Soejarto
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
| | - A Douglas Kinghorn
- Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
| |
Collapse
|
16
|
Dei S, Romanelli MN, Manetti D, Chiaramonte N, Coronnello M, Salerno M, Teodori E. Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR). Bioorg Med Chem 2018; 26:50-64. [DOI: 10.1016/j.bmc.2017.11.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 11/06/2017] [Accepted: 11/09/2017] [Indexed: 10/18/2022]
|
17
|
Teodori E, Dei S, Coronnello M, Floriddia E, Bartolucci G, Manetti D, Romanelli MN, Santo Domingo Porqueras D, Salerno M. N -alkanol- N -cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy. Eur J Med Chem 2017; 127:586-598. [DOI: 10.1016/j.ejmech.2017.01.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Revised: 01/09/2017] [Accepted: 01/12/2017] [Indexed: 11/29/2022]
|
18
|
Ma J, Li J, Tian YS. Synthesis and bioactivity evaluation of 2,3-diaryl acrylonitrile derivatives as potential anticancer agents. Bioorg Med Chem Lett 2017; 27:81-85. [DOI: 10.1016/j.bmcl.2016.11.025] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2016] [Revised: 10/09/2016] [Accepted: 11/11/2016] [Indexed: 01/11/2023]
|
19
|
Xu C, Qin M, Yi J, Wang Y, Chen Y, Zhang B, Zhao Y, Gong P. Copper( ii)-mediated formation of oxazole-4-carbonitrile from acetophenone and coordinated cyanide anion via a radical coupling. RSC Adv 2017. [DOI: 10.1039/c7ra01983a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A protocol for the direct synthesis of 4-aryloxazole-5-carbonitrile from acetophenone was first described.
Collapse
Affiliation(s)
- Congjun Xu
- Key Laboratory of Structure-based Drug Design and Discovery
- Shenyang Pharmaceutical University
- Ministry of Education
- Shenyang 110016
- People's Republic of China
| | - Mingze Qin
- Key Laboratory of Structure-based Drug Design and Discovery
- Shenyang Pharmaceutical University
- Ministry of Education
- Shenyang 110016
- People's Republic of China
| | - Jun Yi
- Key Laboratory of Structure-based Drug Design and Discovery
- Shenyang Pharmaceutical University
- Ministry of Education
- Shenyang 110016
- People's Republic of China
| | - Yanjing Wang
- Key Laboratory of Structure-based Drug Design and Discovery
- Shenyang Pharmaceutical University
- Ministry of Education
- Shenyang 110016
- People's Republic of China
| | - Yanfeng Chen
- Key Laboratory of Structure-based Drug Design and Discovery
- Shenyang Pharmaceutical University
- Ministry of Education
- Shenyang 110016
- People's Republic of China
| | - Bingfu Zhang
- Key Laboratory of Structure-based Drug Design and Discovery
- Shenyang Pharmaceutical University
- Ministry of Education
- Shenyang 110016
- People's Republic of China
| | - Yanfang Zhao
- Key Laboratory of Structure-based Drug Design and Discovery
- Shenyang Pharmaceutical University
- Ministry of Education
- Shenyang 110016
- People's Republic of China
| | - Ping Gong
- Key Laboratory of Structure-based Drug Design and Discovery
- Shenyang Pharmaceutical University
- Ministry of Education
- Shenyang 110016
- People's Republic of China
| |
Collapse
|
20
|
Fusi F, Durante M, Spiga O, Trezza A, Frosini M, Floriddia E, Teodori E, Dei S, Saponara S. In vitro and in silico analysis of the vascular effects of asymmetrical N,N-bis(alkanol)amine aryl esters, novel multidrug resistance-reverting agents. Naunyn Schmiedebergs Arch Pharmacol 2016; 389:1033-43. [PMID: 27351883 DOI: 10.1007/s00210-016-1266-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 06/16/2016] [Indexed: 12/11/2022]
Abstract
Asymmetrical N,N-bis(alkanol)amine aryl esters (FRA77, GDE6, and GDE19) are potent multidrug resistance (MDR) reversers. Their structures loosely remind that of the Ca(2+) antagonist verapamil. Therefore, the aim of this study was to investigate their vascular activity in vitro. Their effects on the mechanical activity of fresh and cultured rat aorta rings on Cav1.2 channel current (I Ca1.2) of A7r5 cells and their cytotoxicity on A7r5 and EA.hy926 cells were analyzed. Docking at the rat α1C subunit of the Cav1.2 channel was simulated in silico. Compounds tested were cytotoxic at concentrations >1 μM (FRA77, GDE6, GDE19) and >10 μM (verapamil) in EA.hy926 cells, or >10 μM (FRA77, GDE6, GDE19) and at 100 μM (verapamil) in A7r5 cells. In fresh rings, the three compounds partly antagonized phenylephrine and 60 mM K(+) (K60)-induced contraction at concentrations ≥1 and ≥3 μM, respectively. On the contrary, verapamil fully relaxed rings pre-contracted with both agents. In cultured rings, 10 μM GDE6, GDE19, FRA77, and verapamil significantly reduced the contractile response to both phenylephrine and K60. Similarly to verapamil, the three compounds docked at the α1C subunit, interacting with the same amino acids residues. FRA77, GDE6, and GDE19 inhibited I Ca1.2 with IC50 values 1 order of magnitude higher than that of verapamil. FRA77-, GDE6-, and GDE19-induced vascular effects occurred at concentrations that are at least 1 order of magnitude higher than those effectively reverting MDR. Though an unambiguous divergence between MDR reverting and vascular activity is of overwhelming importance, these findings consistently contribute to the design and synthesis of novel and potent chemosensitizers.
Collapse
Affiliation(s)
- F Fusi
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via A. Moro 2, 53100, Siena, Italy
| | - M Durante
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via A. Moro 2, 53100, Siena, Italy
| | - O Spiga
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, via A. Moro 2, 53100, Siena, Italy
| | - A Trezza
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, via A. Moro 2, 53100, Siena, Italy
| | - M Frosini
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via A. Moro 2, 53100, Siena, Italy
| | - E Floriddia
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy
| | - E Teodori
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy
| | - S Dei
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy
| | - S Saponara
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via A. Moro 2, 53100, Siena, Italy.
| |
Collapse
|
21
|
Kadioglu O, Saeed ME, Valoti M, Frosini M, Sgaragli G, Efferth T. Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses. Biochem Pharmacol 2016; 104:42-51. [DOI: 10.1016/j.bcp.2016.01.014] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Accepted: 01/20/2016] [Indexed: 12/19/2022]
|
22
|
Kutonova KV, Trusova ME, Stankevich AV, Postnikov PS, Filimonov VD. Matsuda-Heck reaction with arenediazonium tosylates in water. Beilstein J Org Chem 2015; 11:358-62. [PMID: 25977709 PMCID: PMC4419561 DOI: 10.3762/bjoc.11.41] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Accepted: 03/01/2015] [Indexed: 11/23/2022] Open
Abstract
An environmentally friendly Matsuda–Heck reaction with arenediazonium tosylates has been developed for the first time. A range of alkenes was arylated in good to quantitative yields in water. The reaction is significantly accelerated when carried out under microwave heating. The arylation of haloalkylacrylates with diazonium salts has been implemented for the first time.
Collapse
Affiliation(s)
- Ksenia V Kutonova
- Department of Biotechnology and Organic Chemistry, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - Marina E Trusova
- Department of Biotechnology and Organic Chemistry, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - Andrey V Stankevich
- Laboratory of Materials and Technologies of Liquid Crystal Devices, Institute of Chemistry of New Materials NAS Belarus, 220141, Minsk, Belarus
| | - Pavel S Postnikov
- Department of General and Inorganic Chemistry, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - Victor D Filimonov
- Department of Biotechnology and Organic Chemistry, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia
| |
Collapse
|
23
|
Wang R, Bao W. Copper promoted radical addition/cyclization of azobisisobutyronitrile with arylacrylamides: a convenient process to synthesize 3-(2′-cyano alkyl) oxindoles. RSC Adv 2015. [DOI: 10.1039/c5ra07739g] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
A CuI promoted radical addition/cyclization of azobisisobutyronitrile with alkenes for the preparation of 3-(2′-cyano alkyl) oxindoles was developed.
Collapse
Affiliation(s)
- Ruihong Wang
- Department of Chemistry
- Zhejiang University (Xixi Campus)
- Hangzhou 310028
- People's Republic of China
| | - Weiliang Bao
- Department of Chemistry
- Zhejiang University (Xixi Campus)
- Hangzhou 310028
- People's Republic of China
| |
Collapse
|
24
|
Dei S, Coronnello M, Floriddia E, Bartolucci G, Bellucci C, Guandalini L, Manetti D, Romanelli MN, Salerno M, Bello I, Mini E, Teodori E. Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters. Eur J Med Chem 2014; 87:398-412. [PMID: 25282263 DOI: 10.1016/j.ejmech.2014.09.084] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Revised: 09/12/2014] [Accepted: 09/26/2014] [Indexed: 11/16/2022]
Abstract
As a continuation of our research on potent and efficacious P-gp-dependent multidrug resistance (MDR) reversers, several new N,N-bis(alkanol)amine aryl esters were designed and synthesized, varying the aromatic moieties or the length of the methylenic chain. The new compounds were tested on doxorubicin-resistant erythroleukemia K562 cells (K562/DOX) in the pirarubicin uptake assay, where most of the new compounds were shown to be active. In particular the asymmetrical compounds, characterized by two linkers of different length, generally showed fairly high activities as MDR reversers. Some selected compounds (isomers 15-17) were further studied by evaluating their doxorubicin cytotoxicity enhancement (reversal fold, RF) on the K562/DOX cell line. The results of both pharmacological assays indicate that compounds 16 (GDE6) and 17 (GDE19) could be interesting leads for the development of new P-gp dependent MDR modulators.
Collapse
Affiliation(s)
- Silvia Dei
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy.
| | - Marcella Coronnello
- Dipartimento di Scienze della Salute, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Elisa Floriddia
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Gianluca Bartolucci
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Cristina Bellucci
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Luca Guandalini
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Dina Manetti
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Maria Novella Romanelli
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Milena Salerno
- Université Paris 13, Sorbonne Paris Cité, Laboratoire CSPBAT, CNRS (UMR 7244), UFR-SMBH, 74 Rue Marcel Cachin, 93017 Bobigny, France
| | - Ivan Bello
- Université Paris 13, Sorbonne Paris Cité, Laboratoire CSPBAT, CNRS (UMR 7244), UFR-SMBH, 74 Rue Marcel Cachin, 93017 Bobigny, France
| | - Enrico Mini
- Dipartimento di Scienze della Salute, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Elisabetta Teodori
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| |
Collapse
|
25
|
Orlandi F, Coronnello M, Bellucci C, Dei S, Guandalini L, Manetti D, Martelli C, Romanelli MN, Scapecchi S, Salerno M, Menif H, Bello I, Mini E, Teodori E. New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR). Bioorg Med Chem 2012; 21:456-65. [PMID: 23245571 DOI: 10.1016/j.bmc.2012.11.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2012] [Revised: 11/07/2012] [Accepted: 11/12/2012] [Indexed: 10/27/2022]
Abstract
As a continuation of previous research on a new series of potent and efficacious P-gp-dependent multidrug resistant (MDR) reversers with a N,N-bis(cyclohexanol)amine scaffold, we have designed and synthesized several analogs by modulation of the two aromatic moieties linked through ester functions to the N,N-bis(cyclohexanol)amine, aiming to optimize activity and to extend structure-activity relationships (SAR) within the series. This scaffold, when esterified with two different aromatic carboxylic acids, gives origin to four geometric isomers (cis/trans, trans/trans, cis/cis and trans/cis). The new compounds were tested on doxorubicin-resistant erythroleukemia K562 cells (K562/DOX) in the pirarubicin uptake assay. Most of them resulted in being potent modulators of the extrusion pump P-gp, showing potency values ([I](0.5)) in the submicromolar and nanomolar range. Of these, compounds 2b, 2c, 3d, 5a-d and 6d, showed excellent efficacy with a α(max) close to 1. Selected compounds (2d, 3a, 3b, 5a-d) were further studied to evaluate their doxorubicin cytotoxicity potentiation (RF) on doxorubicin-resistant erythroleukemia K562 cells and were found able to enhance significantly doxorubicin cytotoxicity on K562/DOX cells. The results of both pirarubicin uptake and the cytotoxicity assay, indicate that the new compounds of the series are potent P-gp-mediated MDR reversers. They present a structure with a mix of flexible and rigid moieties, a property that seems critical to allow the molecules to choose the most productive of the several binding modes possible in the transporter recognition site. In particular, compounds 5c and 5d, similar to the already reported analogous isomers 1c and 1d,(29) are potent and efficacious modulators of P-gp-dependent MDR and may be promising leads for the development of MDR-reversal drugs.
Collapse
Affiliation(s)
- Francesca Orlandi
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
N,N-Bis(cyclohexanol)amine aryl esters inhibit P-glycoprotein as transport substrates. Biochem Pharmacol 2011; 82:1822-31. [DOI: 10.1016/j.bcp.2011.08.025] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Revised: 08/29/2011] [Accepted: 08/30/2011] [Indexed: 11/21/2022]
|
27
|
Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. JOURNAL OF NATURAL PRODUCTS 2011; 74:1539-55. [PMID: 21650152 PMCID: PMC3158731 DOI: 10.1021/np200391c] [Citation(s) in RCA: 145] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Along with compounds from terrestrial microorganisms, the constituents of higher plants have provided a substantial number of the natural product-derived drugs used currently in Western medicine. Interest in the elucidation of new structures of the secondary metabolite constituents of plants has remained high among the natural products community over the first decade of the 21st century, particularly of species that are used in systems of traditional medicine or are utilized as botanical dietary supplements. In this review, progress made in the senior author's laboratory in research work on naturally occurring sweeteners and other taste-modifying substances and on potential anticancer agents from tropical plants will be described.
Collapse
Affiliation(s)
- A Douglas Kinghorn
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA.
| | | | | | | |
Collapse
|
28
|
Zhang L, Ma S. Efflux pump inhibitors: a strategy to combat P-glycoprotein and the NorA multidrug resistance pump. ChemMedChem 2010; 5:811-22. [PMID: 20373322 DOI: 10.1002/cmdc.201000006] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Multidrug resistance (MDR) is the cause of an ever-increasing number of problems in the treatment of cancers and bacterial infections. The active efflux of drugs contributes significantly to this phenomenon. This minireview summarizes recent advances in combating MDR, with particular emphasis on natural and synthetic efflux pump inhibitors of P-glycoprotein in resistant tumor cells and of the NorA MDR pump in Staphylococcus aureus.
Collapse
Affiliation(s)
- Ling Zhang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, PR China
| | | |
Collapse
|
29
|
Martelli C, Coronnello M, Dei S, Manetti D, Orlandi F, Scapecchi S, Novella Romanelli M, Salerno M, Mini E, Teodori E. Structure−Activity Relationships Studies in a Series of N,N-Bis(alkanol)amine Aryl Esters as P-Glycoprotein (Pgp) Dependent Multidrug Resistance (MDR) Inhibitors. J Med Chem 2010; 53:1755-62. [DOI: 10.1021/jm9016174] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Cecilia Martelli
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Marcella Coronnello
- Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Silvia Dei
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Dina Manetti
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Francesca Orlandi
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Serena Scapecchi
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Maria Novella Romanelli
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Milena Salerno
- Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Universitè Paris 13, 74 rue Marcel Cachin, 93017 Bobigny, France
| | - Enrico Mini
- Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Elisabetta Teodori
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| |
Collapse
|
30
|
Martelli C, Alderighi D, Coronnello M, Dei S, Frosini M, Le Bozec B, Manetti D, Neri A, Romanelli MN, Salerno M, Scapecchi S, Mini E, Sgaragli G, Teodori E. N,N-bis(Cyclohexanol)amine Aryl Esters: A New Class of Highly Potent Transporter-Dependent Multidrug Resistance Inhibitors. J Med Chem 2009; 52:807-17. [DOI: 10.1021/jm8012745] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Cecilia Martelli
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Daniela Alderighi
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Marcella Coronnello
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Silvia Dei
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Maria Frosini
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Bénédicte Le Bozec
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Dina Manetti
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Annalisa Neri
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Maria Novella Romanelli
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Milena Salerno
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Serena Scapecchi
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Enrico Mini
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Giampietro Sgaragli
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| | - Elisabetta Teodori
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy, Dipartimento di Neuroscienze, Sezione di Farmacologia, Fisiologia e Tossicologia, Università di Siena, via A. Moro 2, 53100 Siena, Italy, Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy, Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Université Paris 13
| |
Collapse
|
31
|
Zhang FY, Du GJ, Zhang L, Zhang CL, Lu WL, Liang W. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res 2008; 26:914-25. [PMID: 19067124 DOI: 10.1007/s11095-008-9793-y] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2008] [Accepted: 11/07/2008] [Indexed: 10/21/2022]
Abstract
PURPOSE Naringenin has shown paradoxical results to modulate the function of multidrug resistance-associated proteins (MRPs). The aim of this study is to interpret whether naringenin can reverse intrinsic and/or acquired resistance of cancer cells to chemotherapeutic agents. METHODS The effects of naringenin on the uptake, retention and cytotoxicity of doxorubicin were investigated in A549, MCF-7, HepG2 and MCF-7/DOX cells. Cellular efflux pathways modulated by naringenin were assessed with their specific substrates and inhibitors. The improved antitumor activity of doxorubicin in combination with naringenin was also investigated in vivo. RESULTS The IC(50) values of doxorubicin in combination with naringenin in A549 and MCF-7 cells were approximately 2-fold lower than that of doxorubicin alone. The increased sensitivity to doxorubicin by naringenin in HepG2 and MCF-7/DOX cells was not observed. Naringenin increased the cellular doxorubicin accumulation through inhibiting doxorubicin efflux in the cells expressing MRPs but not P-gp. In contrast to doxorubicin alone, doxorubicin in combination with naringenin enhanced antitumor activity in vivo with low systemic toxicity. CONCLUSION Naringenin enhances antitumor effect of doxorubicin by selective modulating drug efflux pathways. Naringenin will be a useful adjunct to improve the effectiveness of chemotherapeutic agents in treatment of human cancers.
Collapse
Affiliation(s)
- Fa Yun Zhang
- Protein and Peptide Pharmaceutical Laboratory, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China
| | | | | | | | | | | |
Collapse
|
32
|
Teodori E, Martelli C, Salerno M, Darghal N, Dei S, Garnier-Suillerot A, Gualtieri F, Manetti D, Scapecchi S, Romanelli MN. Isomeric N,N-Bis(cyclohexanol)amine Aryl Esters: The Discovery of a New Class of Highly Potent P-Glycoprotein (Pgp)-dependent Multidrug Resistance (MDR) Inhibitors. J Med Chem 2007; 50:599-602. [PMID: 17256837 DOI: 10.1021/jm0614432] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
A new series of P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors having a N,N-bis(cyclohexanol)amine scaffold have been designed, following the frozen analog approach. With respect to the parent flexible molecules, the new compounds show improved potency and efficacy. Among them, compound 1d, on anthracycline-resistant erythroleukemia K562 cells, is able to completely reverse Pgp-dependent MDR at low nanomolar concentration.
Collapse
Affiliation(s)
- Elisabetta Teodori
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
|